P-25

Early symptom relief following treatment with the oral bradykinin B2 receptor antagonist deucrictibant immediate-release capsule (PHVS416) in patients with hereditary angioedema attacks

M.A. Riedl[1], J. Anderson[2], E. Aygören-Pürsün[3], M.L. Baeza[4], L. Bouillet[5], H. Chapdelaine[6], D.M. Cohn[7], A. Du-Thanh[8], O. Fain[9], H. Farkas[10], J. Greve[11], M. Guilarte[12], D. Hagin[13], R. Hakl[14], J.S. Jacobs[15], A. Kessel[16], S. Kiani-Alikhan[17], P. Králícková[18], H.H. Li[19], R. Lleonart[20], M. Magerl[21], M.E. Manning[22], A. Reshef[23], B. Ritchie[24], G. Spadaro[25], M. Staevska[26], P. Staubach[27], M. Stobiecki[28], G.L. Sussman[29], M.D. Tarzi[30], A. Valerieva[26], W.H. Yang[31], M.H. Jouvin[32], R. Crabbé[33], S. van Leeuwen[34], H. Chen[32], L. Zhu[32], J. Knolle[35], A. Lesage[36], P. Lu[32], M. Maurer[21]

[1]Division of Rheumatology, Allergy and Immunology, University of California San Diego, La Jolla, CA, USA; [2]Clinical Research Center of Alabama, AllerVie Health Birmingham, AL, USA; [3]Department for Children and Adolescents, University Hospital Frankfurt, Goethe University Frankfurt, Frankfurt, Germany; [4]Allergy Department, Hospital General Universitario Gregorio Marañón, Madrid, Spain; [5]National Reference Center for Angioedema (CREAK), Department of Internal Medicine, Grenoble Alpes University, Laboratoire T-RAIG, UMR 5525 TIMC-IMAG (UGA-CNRS), Grenoble, France; [6]CHU de Montréal, Université de Montréal, Montréal, Canada; [7]Department of Vascular Medicine, Amsterdam Cardiovascular Sciences, Amsterdam UMC, University of Amsterdam, Amsterdam, The Netherlands; [8]Department of Dermatology, University Montpellier, Montpellier, France; [9]Department of Internal Medicine, Sorbonne University, AP-HP, Saint Antoine Hospital, Paris, France; [10]Department of Internal Medicine and Haematology, Hungarian Angioedema Center of Reference and Excellence, Semmelweis University, Budapest, Hungary; [11]Department of Otorhinolaryngology, Head and Neck Surgery, Ulm University Medical Center, Ulm, Germany; [12]Allergy Section, Internal Medicine Department, Hospital Universitari Vall d'Hebron, Barcelona, Spain; [13]Allergy and Clinical Immunology Unit, Department of Medicine, Tel Aviv Sourasky Medical Center and Sackler Faculty of Medicine, University of Tel Aviv, Tel Aviv, Israel; [14]Department of Clinical Immunology and Allergology, St. Anne's University Hospital in Brno and Faculty of Medicine, Masaryk University, Brno, Czech Republic, Brno, Czech Republic; [15]Allergy and Asthma Clinical Research, Walnut Creek, CA, USA; [16]Bnai Zion Medical Center, Technion-Israel Institute of Technology, Haifa, Israel; [17]Department of Immunology, Royal Free London NHS Foundation Trust, London, United Kingdom; [18]Institute of Clinical Immunology and Allergy, University Hospital Hradec Kralove, Charles University, Faculty of Medicine in Hradec Kralove, Hradec Kralove, Czech Republic; [19]Institute for Asthma and Allergy, Chevy Chase, MD, USA; [20]Allergology Service, Bellvitge University Hospital, L'Hospitalet de Llobregat, Barcelona, Spain; [21]Institute of Allergology, Charité - Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin and Humboldt-Universität zu Berlin, and Fraunhofer Institute for Translational Medicine and Pharmacology ITMP, Allergology and Immunology, Berlin, Germany; [22]Allergy, Asthma and Immunology Associates, Ltd., Scottsdale, Arizona, USA; [23]Allergy, Immunology and Angioedema Center, Barzilai University Hospital, Ashkelon, Israel; [24]Division of Hematology, Department of Medicine, University of Alberta, Edmonton, AB, Canada; [25]Department of Translational Medical Sciences and Center for Basic and Clinical Immunology Research (CISI), University of Naples Federico II, Napoli, Italy; [26]Department of Allergology, Clinic of Allergology, University Hospital "Alexandrovska", Medical University of Sofia, Sofia, Bulgaria; [27]Department of Dermatology, University Medicine Mainz, Mainz, Germany; [28]Department of Clinical and Environmental Allergology, Jagiellonian University Medical College, Krakow, Poland; [29]Gordon Sussman Clinical Research Inc, Toronto, Canada; [30]Department of Medicine, Brighton and Sussex Medical School, Brighton, United Kingdom; [31]Ottawa Allergy Research Corporation, Department of Medicine, University of Ottawa, Ottawa, ON, Canada; [32]Pharvaris Inc., Lexington, MA, USA; [33]RC Consultancy, Bassins, Switzerland; [34]SLC Consultancy, Woerden, The Netherlands; [35]JCK Consult, Frankfurt, Germany; [36]GrayMatters Consulting, Schilde, Belgium

Introduction

- Approved therapies for hereditary angioedema (HAE) attacks are administered parenterally with substantial treatment burden due to administration time and risk of pain or other injection site reactions[1-4], with treatment of many attacks being delayed or forgone.[5-6]
- An unmet need exists for on-demand oral therapies that are effective and well-tolerated and may reduce the treatment burden enabling prompt administration as recommended by international clinical guidelines.[7-9]
- Deucrictibant immediate-release (IR) capsule (PHVS416) is an investigational formulation containing deucrictibant (PHA121), a highly potent, specific, and orally bioavailable competitive antagonist of the bradykinin B2 receptor.[10-11]
- In the Phase 2 RAPIDe-1 trial (NCT04618211[12]) deucrictibant IR capsule reduced time to onset of symptom relief and to attack resolution measured through the visual analogue scale-3 (VAS-3) and substantially reduced use of rescue medication.[13-14]

Methods

- RAPIDe-1 was a Phase 2, double-blind, placebo-controlled, randomized, crossover, dose-ranging trial of deucrictibant IR capsule for the acute treatment of angioedema attacks in patients with type 1 and 2 HAE.
- A primary analysis was performed including 147 qualifying HAE attacks treated by 62 patients with double-blinded placebo or deucrictibant IR capsule 10, 20, or 30 mg (modified intent-to-treat analysis, mITT = all randomized patients with ≥1 treated HAE attack and VAS results at both pre-treatment and ≥1 post-treatment time point).
- Mean Symptom Complex Severity (MSCS) score and Treatment Outcome Score (TOS) are validated composite scores based on patient-reported symptoms of attacks at the affected body sites, included in ecallantide clinical trials[15-17]. Changes in MSCS score and in TOS from pre-treatment to 4 hours post-treatment were secondary endpoints of RAPIDe-1.
- MSCS is a point-in-time measure of symptom severity:
  - Patient-rated severity of each affected symptom on a categorical scale (0 = normal, 1 = mild, 2 = moderate, 3 = severe)
  - Calculated as average score from all affected body sites involved (symptom complexes)
  - Decrease in score reflects improvement in symptom severity
- TOS is a measure of symptom response to treatment:
  - Patient assessment of response for each affected body site on categorical scale (significant improvement [100], improvement [50], same [0], worsening [-50], significant worsening [-100])
  - Calculated as weighted average of the response at all body sites using pre-treatment severity as weight
  - Increase in score reflects improvement in symptom from pre-treatment
  - Complex Assessment questions evaluate patient-reported change in attack symptoms from pre-treatment
    - A lot better or resolved – a little better – same – a little worse – a lot worse

Results



Figure 1. RAPIDe-1 trial design schematic



Figure 2. Deucrictibant IR capsule significantly reduced MSCS score at 4h



Figure 3. Deucrictibant IR capsule significantly improved TOS at 4h

	Placebo	Deucrictibant IR capsule 10 mg	Deucrictibant IR capsule 20 mg	Deucrictibant IR capsule 30 mg
Number of patients with post-treatment TOS PRO	49	21	16	19
Number of attacks with post-treatment TOS PRO	49	36	28	29
Attacks with onset of all symptom complexes "**a little better**" within 48 hours – n (%)	18 (36.7%)	32 (88.9%)	25 (89.3%)	27 (93.1%)
Median (95% CI) time (hours) to **onset of symptom relief** by KM estimate	7.62 (3.95, -)	1.89 (0.97, 3.97)	2.15 (1.75, 4.00)	1.98 (1.80, 3.87)

Onset of symptom relief = The time point when TOS PRO first reaches at least "A little better" for all symptom complexes affected at baseline, and no new symptom in any other symptom complex is reported. Relief is confirmed if the improvement is sustained at 2 consecutive time points

Table 1. Deucrictibant IR capsule reduced time to onset of symptom relief

	Placebo	Deucrictibant IR capsule 10 mg	Deucrictibant IR capsule 20 mg	Deucrictibant IR capsule 30 mg
Number of patients with post-treatment TOS PRO	49	21	16	19
Number of attacks with post-treatment TOS PRO	49	36	28	29
Attacks with onset of all symptom complexes "**a lot better or resolved**" within 48 hours – n (%)	13 (26.5%)	30 (83.3%)	23 (82.1%)	25 (86.2%)
Median (95% CI) time (hours) to **almost complete or complete symptom relief** by KM estimate	23.28 (5.78, 47.17)	4.02 (3.93, 5.77)	5.93 (3.90, 8.58)	4.12 (3.92, 7.22)

Almost complete or complete symptom relief = The time point when TOS PRO first reaches "*A lot better or resolved*" for all symptom complexes affected at baseline, and no new symptom in any other symptom complex is reported.

Table 2. Deucrictibant IR capsule reduced time to almost complete or complete symptom relief

Conclusions

- **In the Phase 2 RAPIDe-1 trial deucrictibant IR capsule improved symptoms and reduced time to symptom relief and to resolution of HAE attacks**
- **Clinical meaningful improvement of symptoms was observed during the first hours after treatment with deucrictibant IR capsule**

References

[1]Berinert® [package insert], https://labeling.cslbehring.com/pi/us/berinert/en/berinert-prescribing-information.pdf (accessed 25 April 2023). [2]Firazyr® [package insert], https://www.shirecontent.com/PI/PDFs/Firazyr_USA_ENG.pdf (accessed 25 April 2023). [3]Kalbitor® [package insert], https://www.shirecontent.com/PI/PDFs/Kalbitor_USA_ENG.pdf (accessed 25 April 2023). [4]Ruconest® [package insert], https://www.ruconest.com/wp-content/uploads/Ruconest_PI_Apr2020.pdf (accessed 25 April 2023). [5]Tuong LA et al. Allergy Asthma Proc 2014;35:250-4. [6]US Food and Drug Administration, Center for Biologics Evaluation and Research. The voice of the patient – Hereditary angioedema. May, 2018. https://www.fda.gov/media/113509/download (accessed 25 April 2023). [7]Betschel S et al. Allergy Asthma Clin Immunol 2019;15:72. [8]Busse PJ et al. J Allergy Clin Immunol Pract 2021 2021;9:132-50. [9]Maurer M et al. Allergy 2022;77:1961-90. [10]Lesage A et al. Front Pharmacol 2020;11:916. [11]Lesage A et al. Int Immunopharmacol 2022;105:108523. [12]https://clinicaltrials.gov/ct2/show/NCT04618211 (accessed 25 April 2023). [13]Maurer M et al. AAAAI 2023;411; [14]Farkas H et al. 13th C1-inhibitor Deficiency and Angioedema Workshop 2023;O-19. [15]Vernon MK et al. Qual Life Res 2009;18:929-39. [16]Cicardi M et al. N Engl J Med 2010:363:523-31. [17]Levy RJ et al. Ann Allergy Asthma Immunol 2010;104:523-9.

This presentation includes data for an investigational product not yet approved by regulatory authorities

Presented at the 13th C1-inhibitor Deficiency and Angioedema Workshop Budapest (Hungary), 4–7 May 2023